

Edgar Filing: IDENIX PHARMACEUTICALS INC - Form 4

Common Stock	02/23/2012	P	997	A	\$ 2.78	33,276,369	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	1,321	A	\$ 2.85	33,277,690	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	3,117	A	\$ 2.9	33,280,807	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	8,960	A	\$ 2.96	33,289,767	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	427	A	\$ 2.97	33,290,194	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	232	A	\$ 3.04	33,290,426	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	4,336	A	\$ 3.17	33,294,762	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	3,093	A	\$ 3.79	33,297,855	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	39	A	\$ 5.1	33,297,894	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	11,433	A	\$ 5.11	33,309,327	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	7,402	A	\$ 5.46	33,316,729	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	883	A	\$ 5.79	33,317,612	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	436	A	\$ 5.8	33,318,048	I	<u>(1)</u> See Footnote
Common Stock	02/23/2012	P	493	A	\$ 6.52	33,318,541	I	<u>(1)</u> See Footnote

Common Stock	02/23/2012		P	2,133	A	\$ 7.39	33,320,674	I	See Footnote (1)
-----------------	------------	--	---	-------	---	------------	------------	---	------------------------

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Benef Own Follo Repor Trans (Instr
---	--	---	---	--------------------------------------	--	--	---	---	--

Date Exercisable	Expiration Date	Title	Amount or Number of Shares
---------------------	--------------------	-------	--

Code	V	(A)	(D)
------	---	-----	-----

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
NOVARTIS AG LICHSTRASSE 35 BASEL, V8 CH4002				Indirect 10% Owner
NOVARTIS PHARMA AG LICHSTRASSE 35 BASEL, V8 CH4002		X		

Signatures

/s/ Marc Ceulemans, Head Strategic Venture Capital Fund & Pharma Equities 02/23/2012

**Signature of Reporting Person Date

/s/ Felix Eichhorn, Authorized Signatory 02/23/2012

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is indirect beneficial owner of these securities. See attachment.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.